Security
Nasus Pharma Ltd. · NSRX
NSRXNYSE_AMERICANCommon stockCurrentCIK 2029039Updated Oct 20, 2026
NSRX price & chart
Loading TradingView…
AMEX:NSRX on TradingView ↗About the company
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.
In the news
No coverage from other publishers is available.
SEC disclosures
Nasus Pharma Ltd files prospectus supplement (424B5) ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | Q2 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 639,000Source | — | 5,004,000Source | 717,000Source |
| Property, Plant and Equipment, NetUSD | — | — | 14,000Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 203,000Source | 900,000Source | 1,237,000Source | 284,000Source |
| Assets, CurrentUSD | 291,000Source | — | 4,855,000Source | 457,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 59,000Source | — | 515,000Source | 146,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 135,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 4,953,000Source | — | 2,236,000Source | 3,929,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 20,000Source | — | — | 20,000Source |
| Additional Paid in CapitalUSD | 9,582,000Source | — | 21,288,000Source | 9,432,000Source |
| Retained Earnings (Accumulated Deficit)USD | -13,916,000Source | — | -18,520,000Source | -12,664,000Source |
| Stockholders' Equity Attributable to ParentUSD | -4,314,000Source | -4,663,000Source | 2,768,000Source | -3,212,000Source |
| Liabilities and EquityUSD | 639,000Source | — | 5,004,000Source | 717,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 4,953,000Source | — | 2,163,000Source | 3,929,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | 45,000Source | — |
| Accounts Payable, CurrentUSD | 664,000Source | — | 829,000Source | 651,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 73,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | 553,000Source | 844,000Source |
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 447,000Source | 10,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | — | — | 152,000Source | -5,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | -4,918,000Source | -665,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | -3,014,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 14,000Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | 8,920,000Source | 770,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | 980,000Source | 101,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 232,000Source | 916,000Source | 1,291,000Source | 311,000Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | — | — | 2,667,000Source | 743,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -5,805,000Source | -1,552,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -51,000Source | 20,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | -51,000Source | 20,000Source |
| InterestExpenseNonoperatingUSD | — | — | -78,000Source | 29,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,856,000Source | -1,532,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 5,856,000Source | 1,532,000Source |
| Operating ExpensesUSD | — | — | 4,904,000Source | 1,078,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 8,485,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Total RevenueUSD | 1,235,000,000Source | — |
| Operating Income (Loss)USD | -4,904,000Source | -1,078,000Source |
| Net Income (Loss) Attributable to ParentUSD | -5,856,000Source | -1,532,000Source |
| Earnings Per Share, BasicUSD per share | -0.72Source | -0.22Source |
| Earnings Per Share, DilutedUSD per share | -0.72Source | -0.22Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 8,010,126Source | 7,027,725Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 8,010,126Source | 7,027,725Source |
| Interest Expense (non-operating)USD | -78,000Source | 29,000Source |
| Additional Financial Items | ||
| General and Administrative ExpenseUSD | 2,667,000Source | 743,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -5,805,000Source | -1,552,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -0.72Source | -0.22Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -0.72Source | -0.22Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -51,000Source | 20,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | -51,000Source | 20,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -78,000Source | 29,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 5,856,000Source | 1,532,000Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | 5,805,000Source | 1,552,000Source |
| Operating ExpensesUSD | 4,904,000Source | 1,078,000Source |
| Other ExpensesUSD | 423,000Source | 224,000Source |
| Research and Development ExpenseUSD | 2,237,000Source | 335,000Source |
Offerings
Registration 333-298693
Filing attachments
ex107.htm · S-8 · 2026-10-19
Calculation of Filing Fee Tables S-8 Nasus Pharma Ltd ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ───────────────────────────────────────────────────…
Read attachment ↗ex99-1.htm · 6-K · 2026-09-14
Exhibit 99.1 Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis Clinical study to evaluate NS002, the Company’s investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to administration by a health care professional Pivotal Study is planned for the fourth quarter of 2026; topline data readout anticipated first quarter 2027 TEL AVIV, I…
Read attachment ↗ex99-1.htm · 6-K · 2026-09-04
Exhibit 99.1 Dear Nasus Pharma Ltd. Shareholders: We cordially invite you to attend the Annual and Special General Meeting of Shareholders of Nasus Pharma Ltd. (the “ Company ”), to be held on October 8, 2026 at 2:00 p.m. Israel time, at the Company’s legal counsel’s office, located at 28 Ha’Arbaa St., Hagag Towers, North Tower, 14 th Floor, Tel Aviv, 6744317 Israel (the “ Meeting ”). At the Meeting, shareholders will be asked to consider and vote on the matters listed in the enclosed Notice …
Read attachment ↗ex99-2.htm · 6-K · 2026-09-04
Exhibit 99.2 NASUS PHARMA LTD. Tel Aviv, Israel PROXY STATEMENT ANNUAL AND SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 8, 2026 The enclosed Proxy Statement is being solicited by the board of directors (the “ Board of Directors ” or the “ Board ”) of Nasus Pharma Ltd. (the “ Company ”) for use at the Company’s annual and special general meeting of shareholders (the “ Meeting ”) to be held on October 8, 2026 at 2:00 p.m. Israel time, or at any adjournment or postponement th…
Read attachment ↗ex107.htm · F-3 · 2026-09-01
Calculation of Filing Fee Tables F-3 Nasus Pharma Ltd ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price…
Read attachment ↗ex99-1.htm · 6-K · 2026-08-19
Exhibit 99.1 Nasus Pharma Announces Transition of Chief Financial Officer TEL AVIV, Israel, August 19, 2026 - Nasus Pharma Ltd. (NYSE American: NSRX) (“Nasus”, “Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry. Mr. Rubin will remain with Nasus through September…
Read attachment ↗